Are total bilirubin and high-sensitivity C-reactive protein independently associated with Type 2 diabetes mellitus in postmenopausal women?

Aleksandra Klisic1, Nebojsa Kavaric1, Ana Ninic2
1Primary Health Care Center, Faculty of Medicine, University of Montenegro, Podgorica, Montenegro, 2Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia

Background: Various studies have reported contradictory results regarding the relationship of total bilirubin and high-sensitivity C-reactive protein levels (hsCRP) with diabetes mellitus Type 2 (DM2). Therefore, we aimed to examine which one of them could be more convenient for the estimation of DM2 risk in postmenopausal women. Materials and Methods: A total of 150 healthy postmenopausal women (mean age 57[53–60] years) and 79 postmenopausal women with DM2 (mean age 66 [61–71] years) were enrolled in cross-sectional study. Examinees were recruited consecutively in the study during their regular check-up visit in the Primary Health Care Center in Podgorica, Montenegro, in a period from October 2012 to May 2016. Anthropometric measurements, biochemical parameters, and blood pressure were obtained. Multivariable logistic regression analysis was used to find the independent predictors for DM2 development in postmenopausal women. Results: Age, waist circumference, and total bilirubin were the independent predictors for DM2 development in postmenopausal women (odds ratio [OR] =1.224, 95% confidence interval [CI] [1.117–1.341], P< 0.001; OR = 1.137, [95% CI = 1.036–1.215], P< 0.001, and OR = 0.727, [95% CI = 0.611–0.866], P< 0.001, respectively), whereas hsCRP lost its independent predictive role (OR = 1.155, [95% CI = 0.854–1.560], P= 0.349). Conclusion: Unlike hsCRP, total bilirubin independently correlated with DM2 in postmenopausal women.

Key words: Diabetes, inflammation, postmenopausal, total bilirubin

INTRODUCTION

Postmenopausal women are at increased cardiometabolic risk as compared with women in reproductive age,[1] mainly due to hormonal changes which might lead to increase in visceral fat, resulting in insulin resistance occurrence.

Obesity is regarded as a state of inflammation and oxidative stress with compromised antioxidant defense.[2] The enlarged visceral adipose tissue represents the milieu of increased production of reactive oxygen species (ROS) and proinflammatory adipokines and cytokines.[2-4] The above mechanisms together have been reported in modulating insulin signaling pathways and thus aggravating insulin resistance and inducing cardiometabolic disorders.[1,2]

Mildly elevated levels of total bilirubin (i.e., above physiological level) are regarded to have protective properties, acting like an anti-oxidant and anti-inflammatory molecule due to its ability to scavenge ROS and to suppress the oxidation of lipids and lipoproteins.[5] In line with this, many studies conducted so far reported the beneficial role of moderately high bilirubin in cardiometabolic disorders, like in metabolic syndrome (MetS),[5-7] diabetes mellitus Type 2 (DM2),[8,9] as well as cardiovascular disease (CVD).[10,11]
Contradictory to the above hypothesis, various other group of studies have questioned the association of lower total bilirubin with MetS,[12-14] DM2,[15,16] and CVD.[17,18]

In addition, in vitro investigations have reported that bilirubin may act as a pro-oxidant in endothelial cells that were exposed to glucose[19,20] thus further making confusion of anti-oxidant properties of this biomarker.

On the other hand, inflammation as measured with high-sensitivity C-reactive protein (hsCRP) was not associated with increased risk of incident DM2,[21] while some others have shown its association with DM2 in women, but not in men.[22]

On the basis of the various contradictory results reported regarding the relationship of total bilirubin and hsCRP with DM2, we aimed to examine which one of them could be more convenient for estimation of DM2 risk in the cohort of postmenopausal women.

MATERIALS AND METHODS

Study population
The examined groups comprised 150 healthy postmenopausal women (mean age 57 [range 53–60] years) and 79 postmenopausal women with DM2 (mean age 66 [range 61–71] years) who volunteered to participate in the study. Examinees were recruited consecutively in the study during their regular check-up visit in the Primary Health Care Center in Podgorica, Montenegro, in a period from October 2012 to May 2016. Women were considered to be postmenopausal if reported the absence of menstrual bleeding for >1 year. Medical history and clinical examinations were obtained on the same day.

Inclusion criteria for the control group were as follows: healthy postmenopausal women not receiving hormone replacement therapy or any other medication in the past 6 months, as well as nonsmokers. In addition, all women who had fasting glucose ≥5.6 mmol/L, but ≤6.9 mmol/L, were asked to undergo a 2-h oral glucose tolerance test. Women with fasting glucose ≥7.0 mmol/L or with 2-h postload glucose ≥11.1 mmol/L were excluded from the control study group but were included in the case group with DM2.[1,23,24]

The methods and assays used to include postmenopausal women with DM2 have been described in detail elsewhere.[23,24] Exclusion criteria for all postmenopausal women that participated in the study were: Type 1 DM, hypo- or hyperthyroidism, liver disease other than hepatic steatosis, ethanol consumption >20 g/day, acute inflammatory disease, hsCRP >10 mg/L, malignant diseases, as well as participants who were unwilling to enter the study.[23,24]

All postmenopausal women with DM2 used oral antihyperglycemic therapy (100%), whereas 11.4% of them were on insulin therapy, also. A total of 44.3% and 81% of the women with DM2 were on hypolipidemic drugs and antihypertensive medications, respectively.

Written informed consent was obtained from all examined participants. The Ethical Committee of Primary Health Care Center in Podgorica, Montenegro, approved the study protocol and the research was carried out in compliance with the Declaration of Helsinki.

Anthropometric measurements
All participants underwent basic anthropometric measurements, such as body height (cm), body weight (kg), and waist circumference (WC) (cm). Body mass index (BMI) was calculated, as described previously.[1]

Biochemical analyses
The blood samples for determining biochemical parameters were obtained as described elsewhere.[23,24]

Serum levels of glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triglycerides (TG), uric acid, creatinine, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase, and gamma-glutamyl transferase (GGT), were measured as described previously,[23,24] using the standardized enzymatic procedure (Roche Cobas 400, Mannheim, Germany). hsCRP levels were determined using a nephelometric assay (Behring Nephelometer Analyzer, Marburg, Germany).

Blood pressure was measured, and the glomerular filtration rate was estimated using creatinine in the Modification of Diet in Renal Disease Study equation (eGFR\textsubscript{MDRD}), as described elsewhere.[1,23]

Statistical analysis
Results are expressed as arithmetic mean (standard deviation) for normally distributed variables, as geometric mean and 95% confidence interval (CI) for the mean for log-normally distributed variables and as median (interquartile range) for skewed distributed variables. Differences in continuous variables between postmenopausal women with and without DM2 were tested using Student’s t-test for normally and log-normally distributed variables and Mann-Whitney test for skewed distributed variables. Chi-square test was used for testing differences in categorical variables. The association between variables was assessed using Spearman’s nonparametric
correlation analysis. Using univariable and multivariable logistic regression analysis, we tested the risk for diabetes development in postmenopausal women. Multivariable adjustment was made for all continuous variables, which were statistically different between postmenopausal women with and without DM2, and which were correlated with DM2, (e.g., model included years of age, BMI, WC, HDL-c, TG, creatinine, bilirubin, and hsCRP). Variables in the logistic regression analysis were presented as odds ratio (OR) and 95% CI. Receiver operating characteristic (ROC) curve analysis was used to discriminate postmenopausal women with DM2 from non-DM2 women and to examine the diagnostic performance of each clinical parameter, which was statistically different between the groups. The area under the ROC curve (AUC) between 0.5 and 0.7 could suggest that diagnostic test has low accuracy, between 0.7 and 0.8 diagnostic test has satisfactory accuracy, between 0.8 and 0.9 diagnostic test has good accuracy and AUC higher than 0.9 suggested the excellent accuracy of the diagnostic test. A value of \( P < 0.05 \) was considered as statistically significant. All statistical calculations were performed using the Statistical Package for Social Sciences (SPSS) - PASW Statistics for Windows, Version 18.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

The demographic characteristics of postmenopausal women with and without DM2 are presented in Table 1. Postmenopausal women with DM2 were significantly older, had greater BMI, WC, and longer menopause duration than women without DM2 (\( P < 0.001 \), respectively). DBP was lower in diabetic women (\( P = 0.010 \)). The prevalence of smokers, antihypertensive and hypolipidemic therapies usages were higher among DM2 than non-DM2 patients (\( P < 0.001 \), respectively), since non-DM2 women were not smokers, nor did they use any medicament therapy, as described in methods section.

The DM2 group had lower TC and LDL-c concentrations than controls (\( P < 0.001 \), respectively). Furthermore, the patients had lower HDL-c concentration but higher concentrations of TG than the control group (\( P < 0.001 \), respectively). Lower total bilirubin concentration was determined in DM2 patients than in controls (\( P < 0.001 \)). Glucose, uric acid, creatinine, hsCRP concentrations, and GGT activities were higher (\( P < 0.001 \), respectively), but eGFR was lower in patients with DM2 than in controls (\( P < 0.001 \)).

Spearman’s correlation analysis indicated statistically significant negative correlations between total bilirubin and variables such as age, menopause duration, BMI, WC, SBP, TG, glucose, creatinine, hsCRP, and positive correlations between total bilirubin and HDL-c, AST, eGFR\(_{\text{MDRD}}\). HsCRP correlated positively with age, menopause duration, BMI, WC, SBP, DBP, TG, glucose, GGT, uric acid, and creatinine. Negative correlations were determined between hsCRP and HDL-c, as well as between hsCRP and eGFR\(_{\text{MDRD}}\) [Table 2].

To assess the effects of variables on diabetes occurrence, we used univariable logistic regression analysis [Table 3]. Age, BMI, WC, HDL-c, TG, creatinine, total bilirubin, and hsCRP showed significant OR in univariable logistic regression [Table 3]. As age rose for 1 year, WC for 1 cm, BMI for 1 kg/m\(^2\), and hsCRP for 1 mg/L, odds for DM2 development in postmenopausal women increased for 28%, 13%, 23%, and 34.7%, respectively. Odds for DM2

| Table 1: Demographic characteristics, laboratory, and clinical parameters of postmenopausal women |
|----------------------------------|-----------------|------------------|----------|
|                                 | Control group   | Diabetic group   | \( P \)  |
| \( n \)                          | 150             | 79               |          |
| Age (years)                      | 57 (53-60)      | 66 (61-71)       | <0.001   |
| BMI (kg/m\(^2\))\(^*\)          | 26.1 (25.4-26.8)| 30.5 (29.4-31.6) | <0.001   |
| WC (cm)\(^**\)                  | 89 (79-99)      | 105 (98-112)     | <0.001   |
| SBP (mmHg)                      | 130±25          | 135±16           | 0.087    |
| DBP (mmHg)                      | 84±14           | 79±10            | 0.010    |
| Smoking habits (smoker/nonsmoker)| 0/150           | 12/67            | <0.001   |
| HDL-C (mmol/L)                  | 1.2/67          | 35/44            | <0.001   |
| Antihypertensives (yes/no)      | 0/150           | 64/15            | <0.001   |
| Antihyperglycemics (yes/no)     | 0/150           | 79/0             | <0.001   |
| Insulin (yes/no)                | 0/150           | 9/70             | <0.001   |
| Menopause duration (years)      | 4 (2-9)         | 13 (8-18)        | <0.001   |
| TC (mmol/L)                     | 6.47±1.05       | 5.71±1.13        | <0.001   |
| LDL-C (mmol/L)                  | 1.69±0.42       | 1.31±0.30        | <0.001   |
| GGT (U/L)                       | 4.31±1.02       | 3.47±1.00        | <0.001   |
| TG (mmol/L)\(^*\)              | 1.29 (1.20-1.39)| 1.89 (1.71-2.09) | <0.001   |
| Glucose (mmol/L)\(^**\)        | 5.2 (5.0-5.7)   | 7.1 (6.5-8.5)    | <0.001   |
| Total bilirubin (µmol/L)\(^**\)| 7.5 (6.2-10.2)  | 5.3 (4.1-7.1)    | <0.001   |
| AST (U/L)\(^**\)               | 18 (16-21)      | 18 (16-22)       | 0.325    |
| ALT (U/L)\(^**\)               | 18 (14-23)      | 19 (15-25)       | 0.521    |
| GGT (U/L)\(^**\)               | 19 (9-15)       | 17 (13-23)       | <0.001   |
| Uric acid (µmol/L)              | 262±65          | 302±86           | <0.001   |
| Creatinine (µmol/L)\(^**\)     | 55 (50-61)      | 68 (57-77)       | <0.001   |
| eGFR\(_{\text{MDRD}}\) (mL/min/1.73 m\(^2\))\(^**\) | 101 (96-104) | 74 (63-93) | <0.001 |
| hsCRP (mg/L)\(^*\)             | 0.98 (0.83-1.16)| 2.10 (1.72-2.56)| <0.001   |

Data are presented as arithmetic means±SD and compared with Student’s \( t \)-test. *Log-normally distributed data are presented as geometric mean (95% CI) and compared with Student’s \( t \)-test after logarithmic transformation; **Skewed distributed data are presented as median (IQR) and compared with Mann–Whitney test. IQR=Interquartile range; CI=Confidence interval; BMI=Body mass index; WC=Waist circumference; TC=Total cholesterol; HDL-C=High-density lipoprotein cholesterol; LDL-C=Low-density lipoprotein cholesterol; TG=Triglycerides; AST=Aspartate aminotransferase; ALT=Alanine aminotransferase; GGT=Gamma-glutamyl transferase; eGFR\(_{\text{MDRD}}\)=Estimated glomerular filtration rate; hsCRP=High-sensitivity C-reactive protein; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; SD=Standard deviation.
Klisic, et al.: Bilirubin and hsCRP in Type 2 diabetes in postmenopausal women

Table 2: Associations between total bilirubin and high-sensitivity C-reactive protein with other clinical parameters | Total bilirubin (µmol/L) | hsCRP (mg/L) |
--- | --- | --- |
Age (years) | −0.232** | 0.175** |
Menopause duration (years) | −0.230** | 0.330** |
BMI (kg/m²) | −0.162* | 0.512** |
WC (cm) | −0.251** | 0.546** |
SBP (mmHg) | −0.190** | 0.318** |
DBP (mmHg) | −0.032 | 0.170* |
TC (mmol/L) | 0.075 | −0.075 |
HDL-C (mmol/L) | 0.341** | −0.299** |
LDL-C (mmol/L) | 0.044 | −0.046 |
TG (mmol/L) | −0.360** | 0.204** |
Glucose (mmol/L) | −0.312** | 0.256** |
Total bilirubin (µmol/L) | −0.111 | −0.111 |
AST (IU/L) | 0.146* | −0.062 |
ALT (IU/L) | 0.078 | 0.038 |
GGT (IU/L) | −0.077 | 0.286** |
Uric acid (µmol/L) | −0.038 | 0.384** |
Creatinine (µmol/L) | −0.162* | 0.191** |
eGFR_{MDRD} (mL/min/1.73 m²) | 0.211** | −0.182* |
hsCRP (mg/L) | −0.038 | 0.185|

Data are presented as correlation coefficient (ρ), *P<0.05; **P<0.01. BMI=Body mass index; WC=Waist circumference; TC=Total cholesterol; HDL-C=High-density lipoprotein cholesterol; LDL-C=Low-density lipoprotein cholesterol; TG=Triglycerides; AST=Aspartate aminotransferase; ALT=Alanine aminotransferase; GGT=Gamma-glutamyl transferase; eGFR_{MDRD}=Estimated glomerular filtration rate; hsCRP=High-sensitivity C-reactive protein; SBP=Systolic blood pressure; DBP=Diastolic blood pressure

Table 3: Univariable and multivariable logistic regression analysis for the associations of clinical parameters and diabetes mellitus Type 2 development in postmenopausal women

| Predictors | Unadjusted OR (95% CI) | P | Nagelkerke (R²) |
--- | --- | --- | --- |
Age (years) | 1.280 (1.198–1.368) | <0.001 | 0.473 |
BMI (kg/m²) | 1.130 (1.094–1.174) | <0.001 | 0.400 |
HDL-C (mmol/L) | 0.047 (0.017–0.129) | <0.001 | 0.279 |
TG (mmol/L) | 2.600 (1.764–3.807) | <0.001 | 0.170 |
Creatinine (µmol/L) | 1.138 (1.093–1.174) | <0.001 | 0.365 |
Total bilirubin (µmol/L) | 0.735 (0.645–0.837) | <0.001 | 0.185 |
hsCRP (mg/L) | 1.347 (1.176–1.544) | <0.001 | 0.122 |

Model: Age, WC, BMI, HDL-C, TG, creatinine, total bilirubin, hsCRP, BMI=Body mass index; WC=Waist circumference; HDL-C=High-density lipoprotein cholesterol; TG=Triglycerides; hsCRP=High-sensitivity C-reactive protein; OR=Odds ratio; CI=Confidence intervals

To determine the potential benefit of the single parameter to discriminate postmenopausal women that had DM2 from those who did not have it, ROC analysis was used [Table 4]. The single parameter discriminatory abilities for BMI, WC, HDL-c, TG, creatinine, total bilirubin, hsCRP (all AUCs between 0.7 and 0.8) could suggest satisfactory accuracy for each diagnostic tool. The cutoff for total bilirubin was 7.35 µmol/L. AUC for age and WC were between 0.8 and 0.9 (0.845 for both) and suggested good accuracy for each diagnostic tool to discriminate postmenopausal women who had DM2 from those who did not have it. We also investigated the potential benefit of traditional risk factors used as a single parameter but afterward put in the model to test its accuracy as a diagnostic procedure. The calculated AUC for the model (AUC=0.956) indicated that this diagnostic procedure had an excellent accuracy [Figure 1]. Furthermore, this diagnostic procedure had high sensitivity (93.7%), suggesting its potential usage as a screening tool in population of postmenopausal women to detect DM2 in those who really had it.

**DISCUSSION**

Although contradictory results exist in literature when concerning the protective role of total bilirubin in cardiometabolic diseases, the current study reported...
lower levels of serum total bilirubin in postmenopausal women with DM2, compared to nondiabetic counterparts. In addition, high inflammation (as measured with hsCRP) correlated positively, whereas total bilirubin correlated negatively with unfavorable cardiometabolic risk factors in examined cohort of postmenopausal women. However, in multivariable logistic regression analysis advanced age, higher WC, and lower serum total bilirubin levels were shown to be the independent predictors for DM2 development. On the other hand, hsCRP lost its independent predictive role for DM2 development.

Our results are contrary to the study conducted by Thorand et al.,[22] which reported the association of hsCRP with incident DM2 in women. On the other hand, our results are in agreement with recent study showing that hsCRP was not associated with increased risk of incident DM2 when stratified by baseline glycated hemoglobin (HbA1c) levels. Namely Pan et al.[21] confirmed the positive relationship between CRP and DM2 only among those participants who had already had high HbA1c levels (i.e., undiagnosed diabetes), but not in those having low HbA1c levels (i.e., incident diabetes), suggesting that high CRP levels might be rather hyperglycemia by-product, instead of its direct contribution to the development of incident DM2.

As far as total bilirubin levels are concerned, our results are in line with previous findings[6,8,9] that confirmed the association of total bilirubin with DM2. In addition, in longitudinal study that comprised nearly 6000 Korean men, low serum total bilirubin level was shown to provide additional information for predicting future development of DM2 in healthy individuals.[25]

Abbasi et al.[9] performed the Mendelian randomization in a prospective cohort of nearly 3400 participants free of DM2 at baseline, and confirmed the causal link between bilirubin level and risk of DM2, thus supporting its protective role in diabetes.

Anti-inflammatory and antioxidant properties of bilirubin may be explained by its ability to scavenge ROS by inhibiting the activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, showing that in cultured vascular endothelial and mesangial cells, bilirubin significantly inhibited NADPH-dependent superoxide production in high glucose-induced production of ROS.[26] On the contrary, there are many studies which questioned the role of this biomarker in DM2. Yeh et al.[16] found bilirubin levels to be even higher in the group with DM2, compared with the healthy control group, and also indicated that total bilirubin does not correlate with predictors of cardiovascular risk in the population with DM2. In line with this, Wang et al.[15] did not show the association between serum total bilirubin levels and incident DM2 in the adult population. Similar results that also rejected the hypothesis of independent relationship between serum total bilirubin levels and incident DM2 were shown in a longitudinal study during 6-year follow-up[27] that comprised >2000 participants who were normoglycemic at baseline, where

| Predictors          | AUC (95% CI)    | SE   | Sensitivity (%) | Specificity (%) | P   |
|---------------------|-----------------|------|-----------------|-----------------|-----|
| Age (years)         | 0.845 (0.791-0.889) | 0.030 | 79.9           | 80.0            | <0.001 |
| WC (cm)             | 0.845 (0.792-0.890) | 0.025 | 91.1           | 62.7            | <0.001 |
| BMI (kg/m²)         | 0.748 (0.687-0.803) | 0.032 | 73.4           | 65.3            | <0.001 |
| HDL-C (mmol/L)      | 0.767 (0.707-0.820) | 0.031 | 82.3           | 61.3            | <0.001 |
| TG (mmol/L)         | 0.729 (0.667-0.786) | 0.035 | 75.9           | 66              | <0.001 |
| Creatinine (µmol/L) | 0.781 (0.721-0.832) | 0.036 | 59.5           | 94.7            | <0.001 |
| Total bilirubin (µmol/L) | 0.760 (0.691-0.829) | 0.035 | 55.7           | 87.3            | <0.001 |
| hsCRP (mg/L)        | 0.767 (0.707-0.820) | 0.031 | 83.3           | 61.3            | <0.001 |

BMI=Body mass index; WC=Waist circumference; HDL-C=High density lipoprotein cholesterol; TG=Triglycerides; hsCRP=High-sensitivity C-reactive protein; ROC=Receiver operating characteristic; AUC=Area under the ROC curve; CI=Confidence interval; SE=Standard error

![Figure 1: Receiver operating characteristic curve for models discriminative ability for diabetes mellitus Type 2 development in postmenopausal women. Model: Age, waist circumference, body mass index, high density lipoprotein cholesterol, triglycerides, total bilirubin, high-sensitivity C-reactive protein, creatinine](image-url)
no significant association with prediabetes was shown. Furthermore, the gender difference in response to oxidative stress caused by glycemic variability might be an important underlying factor when evaluating the protective role of total bilirubin[28] in DM2. In a longitudinal study during 5-year follow-up,[29] no association between baseline total bilirubin and incident MetS in males, but a significant inverse association in females has been reported. However, after adjustment for insulin resistance, this inverse association in females became nonsignificant.[29] In another study, the bilirubin level within the physiological range was shown to be the independent predictor for glycemic variability only in females with DM2.[28] In line with this, bilirubin levels were independently correlated with thiobarbituric acid reactive substances (marker of oxidative stress) in women, but not in men, thus suggesting that bilirubin was a poor indicator for oxidative stress in men.[30] Studies have also reported insufficient anti-oxidant defense mechanisms in men as compared to women.[28] In addition, women have a higher percentage of body fat than men,[22] presuming that obesity-related inflammation and oxidative stress could have a greater influence on insulin resistance and DM2 development in women than in men.

Cross-sectional design and relatively small sample-size of postmenopausal women are the limitations of our study. Therefore, longitudinal studies with large sample size are needed to confirm our results. Nevertheless, our results show that in addition to traditional risk factors (e.g., BMI, WC, HDL-c, TG, creatinine), including serum total bilirubin and hsCRP indicates an excellent accuracy (AUC = 0.956) of this diagnostic procedure. Furthermore, high sensitivity (93.7%) of this diagnostic procedure suggests its potential usage as a screening tool in postmenopausal women with DM2 to distinguish them from those who do not have DM2.

**CONCLUSION**

Lower total bilirubin independently correlated with DM2 in postmenopausal women, in addition to advanced age and higher WC. On the other hand, hsCRP did not independently correlate with DM2, suggesting that total bilirubin may be a more reliable biomarker than hsCRP when estimating risk for DM2 development. However, including both total bilirubin and hsCRP, in addition to traditional risk factors (e.g., BMI, WC, HDL-c, TG, creatinine), may be useful screening test in predicting women at risk for DM2. Moreover, it is important to note that all of these parameters are cost-effective and can be easily measured.

**Financial support and sponsorship**

This work was financially supported in part by a grant from the Ministry of Education, Science and Technological Development, Republic of Serbia (Project number 175035).

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Klisic A, Kavaric N, Jovanovic M, Soldatovic I, Gligorovic-Barhanovic N, Kotur-Stevuljevic J. Bioavailable testosterone is independently associated with fatty liver index in postmenopausal women. Arch Med Sci 2017;13:1188-96.
2. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-associated oxidative stress: Strategies finalized to improve redox state. Int J Mol Sci 2013;14:10497-538.
3. Papaetis GS, Papakyrakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: Exploring a pathway full of thorns. Arch Med Sci 2015;11:463-82.
4. Klisic A, Kotur-Stevuljevic J, Kavaric N, Martinovic M, Matic M. The association between follicle stimulating hormone and glutathione peroxidase activity is dependent on abdominal obesity in postmenopausal women. Eat Weight Disord 2018;23(1):133-41.
5. Zhong P, Sun DM, Wu DH, Li TM, Liu XY, Liu HY. Serum total bilirubin levels are negatively correlated with metabolic syndrome in aged Chinese women: A community-based study. Braz J Med Biol Res 2017;50:e5252.
6. Nano J, Muka T, Cepeda M, Voortman T, Dhana K, Brahimaj A, et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: A systematic review and meta-analysis of observational evidence. Diabetes Metab 2016;42:389-97.
7. Kim SH, Lee JW, Im JA, Hwang HJ. Increased γ-glutamyltransferase and decreased total bilirubin are associated with metabolic syndrome in Korean postmenopausal women. Clin Chem Lab Med 2010;48:1623-8.
8. Liu M, Li Y, Li J, Lv X, He Y. Elevated serum total bilirubin levels are negatively associated with major diabetic complications among Chinese senile diabetic patients. J Diabetes Complications 2017;31:213-7.
9. Abbasi A, Deetman PE, Corpeleen I, Gansevoort RT, Gans RO, Hillege HL, et al. Bilirubin as a potential causal factor in type 2 diabetes risk: A mendelian randomization study. Diabetes 2015;64:1459-69.
10. Kawamoto R, Ninomiya D, Hasegawa Y, Kasai Y, Kusunoki T, Ohtsuka N, et al. Mildly elevated serum total bilirubin levels are negatively associated with carotid atherosclerosis among elderly persons with type 2 diabetes. Clin Exp Hypertens 2016;38:107-12.
11. Cho HS, Lee SW, Kim ES, Mo EY, Shin JY, Moon SD, et al. Clinical significance of serum bilirubin and gamma-glutamyltransferase levels on coronary atherosclerosis assessed by multidetector computed tomography. Nutr Metab Cardiovasc Dis 2015;25:677-85.
12. Jo J, Yun JE, Lee H, Kimm H, Jee SH. Total, direct, and indirect serum bilirubin concentrations and metabolic syndrome among the Korean population. Endocrinol 2011;39:182-9.
13. Oda E, Aizawa Y. Total bilirubin is inversely associated with metabolic syndrome but not a risk factor for metabolic syndrome in Japanese men and women. Acta Diabetol 2013;50:417-22.
14. Hwang HJ, Kim SH. Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin Chim Acta 2010;411:1496-501.
15. Wang J, Li Y, Han X, Hu H, Wang F, Li X, et al. Serum bilirubin levels and risk of type 2 diabetes: Results from two independent cohorts in middle-aged and elderly Chinese. Sci Rep 2017;7:41338.
16. Yeh SY, Doupis J, Rahangdale S, Horr S, Malhotra A, Veves A. Total serum bilirubin does not affect vascular reactivity in patients with diabetes. Vasc Med 2009;14:129-36.
17. Mahabadi AA, Lehmann N, Möhlenkamp S, Kälsch H, Bauer M, Schulz R, et al. Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: The Heinz Nixdorf Recall study. Clin Res Cardiol 2014;103:647-53.
18. Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: Three mendelian randomization studies and a meta-analysis. J Intern Med 2013;273:59-68.
19. Cohen G, Livovsky DM, Kapitulnik J, Sasson S. Bilirubin increases the expression of glucose transporter-1 and the rate of glucose uptake in vascular endothelial cells. Rev Diabet Stud 2004;3:127-33.
20. Chen S, Khan ZA, Barbin Y, Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004;38:1301-10.
21. Pan A, Wang Y, Yuan JM, Koh WP. High-sensitive C-reactive protein and risk of incident type 2 diabetes: A case-control study nested within the Singapore Chinese Health Study. BMC Endocr Disord 2017;17:8.
22. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007;30:854-60.
23. Klisic A, Kavaric N, Jovanovic M, Zvrko E, Skerovic V, Scepanovic A, et al. Association between unfavorable lipid profile and glycemic control in patients with type 2 diabetes mellitus. J Res Med Sci 2017;22:122.
24. Kavaric N, Klisic A, Ninic A. Are visceral adiposity index and lipid accumulation product reliable indices for metabolic disturbances in patients with type 2 diabetes mellitus? J Clin Lab Anal 2018;32:e22283.
25. Jung CH, Lee MJ, Kang YM, Hwang JY, Jang JE, Leem J, et al. Higher serum bilirubin level as a protective factor for the development of diabetes in healthy Korean men: A 4 year retrospective longitudinal study. Metabolism 2014;63:87-93.
26. Fujii M, Inoguchi T, Sasaki S, Maeda Y, Zheng J, Kobayashi K, et al. Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulating NAD (P)H oxidase. Kidney Int 2010;78:905-19.
27. Oda E. Cross-Sectional and Longitudinal Associations between Serum Bilirubin and Prediabetes in a Health Screening Population. Can J Diabetes 2016;40:270-5.
28. Kim JK, Roh E, Kim MJ, Kim MK, Park KS, Kwak SH, et al. Serum bilirubin levels are positively associated with glycemic variability in women with type 2 diabetes. J Diabetes Investig 2016;7:874-80.
29. Lee YB, Lee SE, Jun JE, Jee JH, Bae JY, Bae JC, Jin SM, et al. Change in Serum Bilirubin Level as a Predictor of Incident Metabolic Syndrome. PLoS One 2016;11:e0168253.
30. Stojnov M, Stefanovic A, Dzingalasevic G, Ivanisevic J, Miljkovic M, Mandic-Radic S, et al. Total bilirubin in young men and women: Association with risk markers for cardiovascular diseases. Clin Biochem 2013;46:1516-9.